In vitro metabolic stability experiments were performed with different hepatocytes (liver cells), including mouse, rat, minipig, and human, revealing insights into the compound's metabolic behavior ...

The company is backed by NFX, also an investor in Mammoth Biosciences ... applied the process of phosphoproteomic analysis to two mouse models of inflammatory bowel disease.

In a UV-induced mouse model of cutaneous squamous cell carcinoma, topical application of NFX-179 gel reduced the formation of new cSCCs by an average of 92% at doses of 0.5% and greater ...

The researchers designed and screened over 100 compounds and identified the drug NFX-179 that fit their requirements. They performed a series of pre-clinical experiments in mouse models and ...